An occlusive thrombus is a blood clot that completely blocks a blood vessel, cutting off blood flow to the tissue downstream. This is the event behind most heart attacks, many strokes, and sudden loss of blood supply to a limb. The word “occlusive” distinguishes it from a non-occlusive thrombus, which narrows the vessel but still allows some blood through. That distinction matters enormously in practice because a fully blocked artery or vein creates an emergency: tissue starts dying within minutes to hours, and treatment has to restore flow fast.
How It Differs From a Partial Blockage
Blood clots inside vessels exist on a spectrum. A mural thrombus clings to the vessel wall and reduces flow without stopping it entirely. Patients with mural thrombi can have symptoms, but the situation is less immediately dire because tissue is still getting some oxygen. An occlusive thrombus, by contrast, seals the vessel shut. In an artery feeding the heart muscle, that means a heart attack. In a major brain artery, it means a stroke. In a leg artery, it means acute limb ischemia, where the limb can be lost if flow is not restored quickly.
Whether a thrombus becomes occlusive depends on the size of the vessel, the speed at which the clot grows, and how much the vessel can compensate through collateral channels. A small thrombus in a large artery might stay non-occlusive for weeks. The same clot in a smaller branch could block everything immediately. This is one reason people with the same underlying disease can have very different outcomes.
What Occlusive Thrombi Are Made Of
The composition of a thrombus depends heavily on where it forms, because blood behaves differently at different flow speeds. Arterial thrombi form under high-flow, high-shear conditions. They tend to be rich in platelets and fibrin, with relatively few red blood cells, giving them a pale or “white” appearance. One study of coronary artery thrombi found they were composed of roughly 43% fibrin and 31% platelets by volume.1Scientific Reports. The distinctive structure and composition of arterial and venous thrombi and pulmonary emboli These platelet-heavy clots form rapidly and are structurally strong and porous.2PubMed Central. Occlusive thrombosis in arteries
Venous thrombi tell a different story. They form in slower-moving blood, where red blood cells have more time to become trapped. In the same study, venous thrombi were about 63% red blood cells and 35% fibrin by volume, with platelets making up less than 1%.1Scientific Reports. The distinctive structure and composition of arterial and venous thrombi and pulmonary emboli This gives them a darker, “red” appearance. The red blood cells inside these clots are often compressed into unusual shapes, further tightening the clot’s structure.
That said, the old textbook split of “white arterial clots” versus “red venous clots” oversimplifies things. Both types contain the same cellular ingredients: red blood cells, platelets, white blood cells, and fibrin. It is only the proportions that shift, driven by differences in blood flow and shear stress.3PubMed. Venous and Arterial Thromboses: Two Sides of the Same Coin? Stroke thrombi, for instance, often show both red blood cell-rich and platelet-rich zones within the same clot.4PubMed Central. Thrombus Structural Composition in Cardiovascular Disease Composition matters for treatment: a platelet-heavy clot responds differently to drugs than a fibrin-and-red-cell clot does, which is why understanding what you are dealing with changes the therapeutic approach.
Why Occlusive Thrombi Form
The classic framework for understanding clot formation inside blood vessels involves three overlapping factors: changes in blood flow (especially stasis or turbulence), damage to the vessel wall, and a blood chemistry that favors clotting.5PubMed Central. Procoagulant activity in hemostasis and thrombosis: Virchow’s triad revisited No single factor is usually enough on its own. Most occlusive events happen when two or three of these conditions coincide.
In arteries, the most common trigger is rupture of an atherosclerotic plaque. These fatty deposits build up in artery walls over decades. When the thin cap covering a plaque cracks open, the material inside is extremely prone to triggering clotting, and a thrombus can form on the exposed surface within seconds.6PubMed. Mechanisms of plaque formation and rupture In some cases, a thrombus also forms over a plaque that has not ruptured but whose surface has eroded, a process called plaque erosion.7Journal of the American College of Cardiology. Mechanisms of plaque vulnerability and rupture Either way, the artery can go from partially narrowed to completely occluded in a matter of minutes.
In veins, the combination of sluggish blood flow and a prothrombotic state is the usual recipe. Immobility after surgery, long-haul travel, cancer, pregnancy, and inherited clotting disorders all raise the risk. Once a clot starts in a deep leg vein, it can grow until the vessel is fully blocked, causing painful swelling and, if a piece breaks off, a pulmonary embolism.
Elevated levels of clotting proteins like prothrombin and fibrinogen are established risk factors, while proteins on the vessel wall recruit platelets and white blood cells to the site of damage.5PubMed Central. Procoagulant activity in hemostasis and thrombosis: Virchow’s triad revisited Blood flow speed matters too. Higher shear rates activate platelets more aggressively, which helps explain why arterial clots are so platelet-heavy and why they form so fast at sites of turbulence around plaques.
Where Occlusive Thrombi Cause the Most Damage
Heart
A heart attack, or acute myocardial infarction, typically happens when a coronary artery thrombus goes occlusive. The heart muscle fed by that artery begins to die. The composition of the occlusive thrombus changes with time: the longer the artery stays blocked, the more the platelet and fibrin makeup of the clot shifts, which directly affects how well clot-busting drugs and mechanical devices work during reperfusion.8PubMed Central. Composition of coronary thrombus in acute myocardial infarction This is part of why the mantra in cardiology is “time is muscle.” Every minute of delay changes the biology of the clot itself, on top of the ongoing tissue death.
Brain
Large-vessel occlusion is among the most dangerous forms of ischemic stroke, cutting off blood to large territories of brain tissue.9Journal of the American College of Cardiology. Management of Acute Ischemic Stroke Due to Large-Vessel Occlusion: JACC Focus Seminar In some patients, the underlying cause is intracranial atherosclerotic disease, where the plaque and clot form inside arteries of the brain itself. This subtype accounts for roughly 10% to 30% of large-vessel occlusion strokes, depending on age and ethnicity, and carries a particularly stubborn reocclusion problem: up to half of these patients re-block after the clot has been removed.10PubMed Central. Large Vessel Occlusion Stroke due to Intracranial Atherosclerotic Disease: Identification, Medical and Interventional Treatment, and Outcomes
Limbs
Acute limb ischemia happens when a peripheral artery or bypass graft is suddenly blocked. The limb turns pale, cold, and painful, and without rapid treatment both the limb and the patient’s life are at risk.11PubMed Central. Acute Limb Ischemia The blockage can come from a clot that formed locally on a diseased artery wall, or from a clot that traveled from the heart or aorta. In rarer circumstances, extreme physiological stress can trigger widespread clotting in multiple arteries simultaneously.12PubMed Central. Intracardiac Thrombosis and Multiple Arterial Thromboembolism with Acute Limb Ischemia: A Rare Complication of Carbon Monoxide Intoxication
Lungs
Pulmonary embolism is not a separate disease from deep vein thrombosis but rather a downstream consequence. A deep vein clot, or a fragment of one, breaks loose, travels through the right side of the heart, and lodges in the pulmonary arteries. The two conditions are generally considered two faces of the same process.13Haematologica. Finding the origin of pulmonary emboli with a total-body magnetic resonance direct thrombus imaging technique A large embolus that blocks a major pulmonary artery can be immediately life-threatening, while smaller ones may cause partial occlusion with chest pain and breathlessness.
How Occlusive Thrombi Are Detected
Imaging plays a central role in confirming an occlusive thrombus and planning treatment. The specific technique depends on where the clot is suspected. CT angiography is the workhorse for stroke and pulmonary embolism because it is fast and widely available. MRI can provide more detailed information about the thrombus itself, including its age, which helps clinicians estimate how the clot will respond to treatment.14PubMed. In vivo noninvasive detection and age definition of arterial thrombus by MRI Ultrasound is the standard first-line test for deep vein thrombosis, where a vein that cannot be compressed under the probe is taken as evidence of a clot.
In stroke care specifically, imaging of the thrombus can reveal its location, size, and some aspects of its composition, all of which influence whether clot-busting drugs, mechanical retrieval, or both are the best route.15PubMed Central. Imaging of occlusive thrombi in acute ischemic stroke Newer direct thrombus imaging methods, using MRI or CT, aim to let clinicians detect clots with greater sensitivity, track how well thrombolysis is working in real time, and catch early re-formation after treatment.16PubMed Central. Direct Thrombus Imaging in Stroke
Drug-Based Treatments
The three main classes of drugs used against occlusive thrombi each target a different part of the clotting process. Thrombolytics, anticoagulants, and antiplatelet agents often work best in combination, but combining them also raises bleeding risk, so the exact recipe depends on the clinical scenario.
Thrombolytics (sometimes called “clot busters”) work by activating the body’s own clot-dissolving system. Tissue plasminogen activator, or tPA, is the most widely used. It binds to fibrin in the clot and converts a nearby enzyme into plasmin, which chews through the fibrin mesh holding the clot together. There is a biological catch, though: tPA itself can paradoxically slow down the very plasmin it generates, which means that simply giving a bigger dose does not always translate into faster reopening of the vessel.17PubMed Central. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin Getting the dosing right is genuinely tricky, and researchers continue to look for ways around this limitation.
Anticoagulants like heparin and warfarin do not dissolve existing clots. Instead, they prevent the clot from growing and reduce the risk of new ones forming. Antiplatelet drugs, including aspirin and clopidogrel, reduce platelet stickiness and are particularly important in arterial disease, where platelets are the dominant clot component. Combining anticoagulants with antiplatelet therapy improves outcomes in acute coronary syndromes compared to antiplatelet therapy alone, but the added bleeding risk means clinicians have to weigh the benefits carefully for each patient.18Journal of Thrombosis and Haemostasis. Combination anticoagulant and antiplatelet therapy in cardiovascular disease In patients who develop atrial fibrillation while already on antiplatelet drugs, switching to an anticoagulant alone may be sufficient rather than stacking the two together.18Journal of Thrombosis and Haemostasis. Combination anticoagulant and antiplatelet therapy in cardiovascular disease
Mechanical and Surgical Clot Removal
When drugs are not enough, or when they are too slow for the clinical emergency, doctors can physically retrieve the clot. Mechanical thrombectomy is now the standard of care for large-vessel occlusion strokes.19PubMed Central. A review of mechanical thrombectomy techniques for acute ischemic stroke A catheter is threaded through the arterial system, usually starting from the groin, up to the blocked brain artery. Modern devices either grab the clot and pull it out (stent retrievers) or suction it away (aspiration catheters). Both approaches have proven effective at reopening brain arteries and reducing procedural times.20Clinical Radiology. Mechanical thrombectomy in acute ischaemic stroke: a review of the different techniques
Each approach has trade-offs. Devices that approach the clot from behind (proximal devices) tend to be faster and allow repeated attempts with fewer complications. Devices that grab the clot from the far side are better at removing the full mass of thrombotic material but carry a higher risk of pushing clot fragments downstream or causing vessel spasm.21PubMed. Mechanical thrombectomy for acute ischemic stroke: thrombus-device interaction, efficiency, and complications in vivo
For acute limb ischemia, surgical thrombectomy using a balloon-tipped catheter remains a standard option. The balloon is passed through the clot, inflated, and then pulled back to drag the clot out. Reported limb-salvage rates with this approach run roughly 70% to 90%.22Journal of Neuroendovascular Therapy. Fogarty Catheter Removal of External Iliac Artery Thrombus Caused by Sheath-Related Thrombus Entrapment Following Mechanical Thrombectomy: A Case Report The advantage of surgical removal is directness: you can pull out a large clot burden quickly and see the vessel’s condition firsthand.
How the Body Resolves Thrombi Naturally
Even without treatment, the body has mechanisms for breaking down clots over time. In veins, this natural resolution depends heavily on whether blood flow resumes around or through the clot. Animal research has shown that when some flow persists past a thrombus, resolution at day eight improved by roughly 46% compared to a situation with complete stasis.23PubMed Central. Recanalization and flow regulate venous thrombus resolution and Matrix metalloproteinases expression in vivo The body recruits immune cells, especially macrophages, to the clot site. These cells cluster around tiny channels that form within the thrombus as it breaks down, a process called intra-thrombus recanalization. Enzymes produced near these channels dissolve the structural scaffold of the clot from the inside out.
This natural process is much too slow to save tissue during an acute occlusion. It matters more in the weeks and months after the initial event, when the question shifts from “can we reopen the vessel?” to “will it stay open?” Understanding how the body resolves clots also informs treatment decisions: anticoagulants are continued after the acute phase partly to create the flow conditions that help the body finish cleaning up residual thrombus.
Occlusive Thrombosis in Children
Thrombosis in children is far less common than in adults, with estimates around 0.07 to 0.49 cases per 10,000 children per year, but when it happens, the risk factors and biology are different enough that adult treatment guidelines do not translate directly.24PubMed Central. Pediatric thrombosis: Risk factors, diagnosis, and prevention strategies Central venous catheters are by far the biggest trigger in hospitalized children, linked to up to 90% of thrombotic events in that setting.24PubMed Central. Pediatric thrombosis: Risk factors, diagnosis, and prevention strategies Infections and inherited clotting tendencies are the other major contributors.
Neonates are at particular risk because their clotting system is still maturing. They have lower levels of the natural anticoagulant proteins that normally keep clotting in check, and their fibrinolytic system, the one responsible for dissolving clots, is not yet fully active. This combination makes newborns more vulnerable to thrombosis while also making treatment more delicate, since the standard drugs were developed and dosed for adult physiology.
Targeted Drug Delivery and Emerging Approaches
One of the biggest problems with current clot-busting drugs is that they circulate through the entire bloodstream, raising bleeding risk everywhere in the body while only a small fraction of the drug reaches the actual clot. Researchers are working on nanoscale delivery systems designed to concentrate thrombolytic drugs directly at the thrombus site. These systems use tiny particles engineered to carry tPA or similar agents and release them in response to external triggers like magnetic fields, ultrasound pulses, or near-infrared light.25PubMed Central. Advances in Nano-Functional Materials in Targeted Thrombolytic Drug Delivery
One approach uses porous, magnetic microbubbles loaded with tPA. The microbubbles can be guided to the thrombus using an external magnet, then burst open with ultrasound to release the drug right where it is needed. In mouse models, this method reduced the remaining thrombus by about two-thirds compared to a standard tPA injection, and the ultrasound-driven release pushed the drug several hundred micrometers deep into the clot.26PubMed Central. Accelerating thrombolysis using a precision and clot-penetrating drug delivery strategy by nanoparticle-shelled microbubbles The penetration part matters because one reason conventional tPA works slowly is that the dense fibrin network of a mature clot is hard for the drug to soak into. These technologies are still in early stages, but they address real, well-understood limitations of current therapy and could eventually make thrombolysis both faster and safer.
The Role of Inherited Clotting Disorders
Inherited conditions that make the blood more prone to clotting, collectively called thrombophilias, include factor V Leiden, prothrombin gene mutations, and deficiencies in proteins C, S, or antithrombin. Discovering you carry one of these can be alarming, and testing for them has become more common. Yet the practical impact on treatment is surprisingly limited. Available evidence does not indicate that most patients with a defined thrombophilia need to be managed differently from patients without one.27PubMed. The thrombophilias: well-defined risk factors with uncertain therapeutic implications The anticoagulants, the duration of treatment, and the decision about whether to treat are driven more by the clinical event itself and the patient’s overall risk profile than by the genetic result. Where thrombophilia testing becomes more useful is in explaining recurrent, unexplained clotting events, or in guiding decisions about anticoagulation during high-risk situations like pregnancy or surgery. But for most people who have had a single clot, the genetic test rarely changes the treatment plan.